DESIGN THERAPEUTICS INC

Insider momentum at Design Therapeutics signals confidence in its nucleotide repeat disorder pipeline—large zero‑cost option grants could boost stock value if clinical milestones succeed.

Design Therapeutics insiders buy 30,000 zero‑cost options amid a price dip—signals confidence and potential upside for investors, despite market caution.